Neurocrine Biosciences, a firm long viewed as a potential acquisition target within biopharma, is now making a major move as a buyer itself.
The company has agreed to acquire Soleno Therapeutics in a deal valued at $2.9 billion, gaining control of Vykat XR (diazoxide choline), a recently approved therapy for hyperphagia in patients with Prader-Willi syndrome. The drug is the first treatment cleared for this condition, which is marked by an uncontrollable drive to eat and can lead to serious complications such as obesity, cardiometabolic issues and even death.
The acquisition follows Neurocrine’s recent push into obesity research, highlighted by a preclinical CRF2 agonist program. It also represents the largest deal in the company’s history since its founding in 1992.
Speaking during an investor call Monday, CEO Kyle Gano said Vykat XR has the potential to become a blockbuster and will immediately contribute to the company’s revenue stream. Chief business development officer Samir Siddhanti emphasized that Soleno’s focus – bridging neurology and endocrinology – aligns closely with Neurocrine’s strategic priorities.
Analysts at Evercore ISI echoed that sentiment in an April 6 note, saying the timing and profile of the asset fit well within Neurocrine’s broader growth narrative. They added that the deal could help fill a gap in the company’s commercial outlook ahead of key pipeline readouts expected after 2027.
Still, some analysts raised concerns about the therapy’s long-term outlook, and Neurocrine’s shares dipped roughly 2% in early trading following the announcement.
Vykat XR has shown strong early momentum since its approval by the U.S. Food and Drug Administration in March 2025. Launched in the second quarter, the drug generated $190 million in sales last year for Soleno, including nearly $100 million ($92 million to be exact) in the fourth quarter alone.
Neurocrine Biosciences plans to expand the drug’s reach by leveraging its existing commercial infrastructure and therapeutic expertise. The San Diego-based company currently markets Ingrezza, used to treat tardive dyskinesia and chorea associated with Huntington’s disease, as well as Crenessity, a CRF1 receptor antagonist for classic congenital adrenal hyperplasia.
Competition in the space is emerging, though recent setbacks among rivals may ease pressure in the near term. Aardvark Therapeutics recently paused a phase 3 trial of its candidate for hyperphagia in Prader-Willi syndrome, while Acadia Pharmaceuticals discontinued development of its intranasal carbetocin program in September 2025 following a late-stage failure.
Gano stated that Soleno was put through a meticulous diligence process before the deal was made so as to assuage any fears analysts might have regarding its value.
Discussing the therapy’s long-term prospects, Eric Benevich, chief commercial officer at Neurocrine Biosciences, noted that its early launch trajectory shows some parallels to that of Crenessity.
Benevich said certain academic institutions and specialized practices care for a concentrated share of PWS patients, but there is also a broader group spread across community-based settings. He noted that most patients are treated outside major centers or highly specialized clinics, which means reaching the full population requires time and sustained outreach.
Strategic Importance for Neurocrine
The Neurocrine deal is centered around Soleno’s key asset, Vykat XR, a first-in-class therapy targeting hyperphagia associated with Prader-Willi syndrome.
For Neurocrine, this acquisition:
- Expands its footprint in rare and endocrine diseases
- Adds a third commercial product to its portfolio
- Strengthens long-term revenue potential
- Enhances pipeline diversification
The move aligns with Neurocrine’s strategy to build a sustainable portfolio of innovative, high-impact therapies.
About Vykat XR and Market Opportunity
The newly acquired drug is a major growth driver for Neurocrine. Vykat XR:
- Is the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome
- Generated around $190 million in its first year
- Has potential to become a blockbuster therapy
This gives Neurocrine access to a niche but underserved market with strong commercial potential and long patent protection extending into the 2040s.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
